Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $61.3 million.

  • Altimmune's Cash & Equivalents rose 9443.46% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 9443.46%. This contributed to the annual value of $37.0 million for FY2024, which is 7264.83% down from last year.
  • As of Q3 2025, Altimmune's Cash & Equivalents stood at $61.3 million, which was up 9443.46% from $183.1 million recorded in Q2 2025.
  • Altimmune's 5-year Cash & Equivalents high stood at $190.3 million for Q4 2021, and its period low was $31.5 million during Q3 2024.
  • In the last 5 years, Altimmune's Cash & Equivalents had a median value of $111.1 million in 2022 and averaged $114.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 122603.99% in 2021, then tumbled by 7264.83% in 2024.
  • Altimmune's Cash & Equivalents (Quarter) stood at $190.3 million in 2021, then crashed by 41.61% to $111.1 million in 2022, then grew by 21.62% to $135.2 million in 2023, then crashed by 72.65% to $37.0 million in 2024, then soared by 65.76% to $61.3 million in 2025.
  • Its last three reported values are $61.3 million in Q3 2025, $183.1 million for Q2 2025, and $49.1 million during Q1 2025.